Effects of hemolysis and lipemia on the COBAS® salicylate and acetaminophen assays compared to GDS assays

Danni Meany, Jeffery Schowinsky, William Clarke

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Objective: We compared the COBAS® acetaminophen and salicylate assays (Roche Diagnostics) with the Stanbio GDS assays (Stanbio Laboratories) that are currently used in our laboratory with respect to interferences from hemolysis and lipemia. Methods: Acetaminophen and salicylate were added into human serum with varying concentrations of hemoglobin or Intralipid® to generate a range of acetaminophen and salicylate concentrations. Then the COBAS® and GDS assays were used to measure the apparent drug concentrations; the H and L indices were measured to determine the extent of hemolysis and lipemia present in each specimen. Results: Both hemolysis and lipemia have less effect on the COBAS® acetaminophen and salicylate assays than on the GDS assays. Conclusions: The COBAS® assays for acetaminophen and salicylate are preferable to the current GDS assays in clinical toxicology laboratories.

Original languageEnglish (US)
Pages (from-to)1486-1488
Number of pages3
JournalClinical Biochemistry
Volume41
Issue number18
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Keywords

  • Acetaminophen
  • Hemolysis
  • Interference
  • Lipemia
  • Salicylate

Fingerprint Dive into the research topics of 'Effects of hemolysis and lipemia on the COBAS® salicylate and acetaminophen assays compared to GDS assays'. Together they form a unique fingerprint.

Cite this